Real life adjuvant chemotherapy uptake and survival in patients with non-small cell lung cancer after complete resection

References

• Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61:212-36
   PubMed Web of Science ®Google Scholar
• Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995;311:899-909
   PubMed Web of Science ®Google Scholar
• Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE collaborative group. J Clin Oncol 2008;26:3552-9
   PubMed Web of Science ®Google Scholar
• NSCLC Meta-analysis Collaborative Group, Arriagada R, Auperin A, et al. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet 2010;357:1267-77
   Google Scholar
• Coello MC, Luketich JD, Litle VR, et al. Prognostic significance of micrometastasis in non-small-cell lung cancer. Clin Lung Cancer 2004;5:214-25
   PubMedGoogle Scholar
• Wisnivesky JP, Smith CB, Packer S, et al. Survival and risk of adverse events in older patients receiving postoperative adjuvant chemotherapy for resected stages II-IIIA lung cancer: observational cohort study. BMJ 2011;343:247-51
   Google Scholar
• Booth CM, Shepherd FA, Peng Y, et al. Adoption of adjuvant chemotherapy for non-small-cell lung cancer: a population-based outcomes study. J Clin Oncol 2010;28:3472-8
   PubMed Web of Science ®Google Scholar
• Williams CD, Garja A, Ganti AK, et al. Use and impact of adjuvant chemotherapy in patients with resected non-small cell lung cancer. Cancer 2014;120:1939-47
   PubMed Web of Science ®Google Scholar
• Goyal G, Silberstein PT. Impact of demographic and health system factors on adjuvant chemotherapy use in stage II non-small cell lung carcinoma: a national cancer database analysis from 2000 to 2012, p 3056. Presented at WCLC 2015, Denver, CO, September 6–9, 2015
   Google Scholar
• Younis T, Al-Fayea T, Virik K, et al. Adjuvant chemotherapy uptake in non-small cell lung cancer. J Thorac Oncol 2008;3:1272-8
   PubMed Web of Science ®Google Scholar
• Kassam F, Shepherd FA, Johnston M, et al. Referral patterns for adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. J Thorac Oncol 2007;2:39-43
   PubMed Web of Science ®Google Scholar
• Massard C, Tran Ba Loc P, Haddad V, et al. Use of adjuvant chemotherapy in non-small cell lung cancer in routine practice. J Thorac Oncol 2009;4:1504-10
   PubMed Web of Science ®Google Scholar
• Hryniuk WM, Goodyear M. The calculation of received dose intensity. J Clin Oncol 1990;8:1935-7
   PubMed Web of Science ®Google Scholar
• Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007;2:706-14
   PubMed Web of Science ®Google Scholar
• Jassem J, Ramlau R, Karnicka-Młodkowska H, et al. A multicenter Randomized phase II study of oral vs. intravenous vinorelbine in advanced non-small-cell lung cancer patients. Ann Oncol 2001;12:1375-81
   PubMed Web of Science ®Google Scholar
• Jensen LH, Osterlind K, Rytter C. Randomized cross-over study of patient preference for oral or intravenous vinorelbine in combination with carboplatin in the treatment of advanced NSCLC. Lung Cancer 2008;62:85-91
   PubMed Web of Science ®Google Scholar
• National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365:395-409
   PubMed Web of Science ®Google Scholar
• Youssef O, Knuuttila A, Piirila P, et al. Presence of cancer associated mutations in exhaled breath condensates of healthy individuals by next generation sequencing. Oncotarget 2017;8:18166-76
   PubMedGoogle Scholar
• Scagliotti GV, Fossati R, Torri V, et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small cell lung cancer. J Natl Cancer Inst 2003;95:1453-61
   PubMed Web of Science ®Google Scholar
• Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. N Engl J Med 2004;350:351-60
   PubMed Web of Science ®Google Scholar
• Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006;7:719-27
   PubMed Web of Science ®Google Scholar
• Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. Engl J Med 2005;352:2589-97
   PubMed Web of Science ®Google Scholar
• Speicher PJ, Gu L, Wang X, et al. Adjuvant chemotherapy after lobectomy for T1–2N0 non-small cell lung cancer: are the guidelines supported? J Natl Compr Canc Netw 2015;13:755-61
   PubMed Web of Science ®Google Scholar
• Stinchcombe TE, Harper HD, Hensing TA, et al. The feasibility of adjuvant carboplatin and docetaxel in patients with curatively resected non-small cell lung cancer. J Thorac Oncol 2008;3:145-51
   PubMed Web of Science ®Google Scholar
• Gu F, Strauss GM, Wisnivesky JP. Platinum-based adjuvant chemotherapy (ACT) in elderly patients with non-small cell lung cancer (NSCLC) in the SEER-Medicare database: comparison between carboplatin- and cisplatin-based regimens. J Clin Oncol 2011;29(15 suppl):7014
   Web of Science ®Google Scholar
• Strauss GM, Herndon JE 2nd, Maddaus MA, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 2008;26:5043-51
   PubMed Web of Science ®Google Scholar
• Sorensen SF, Carus A, Meldgaard P. Intravenous or oral administration of vinorelbine in adjuvant chemotherapy with cisplatin and vinorelbine for resected NSCLC. Lung Cancer 2015;88:167-73
   PubMed Web of Science ®Google Scholar
• O’Brien MER, Szczesna A, Karnicka H, et al. Vinorelbine alternating oral and intravenous plus carboplatin in advanced non-small-cell lung cancer: results of a multicentre phase II study. Ann Oncol 2004;15:921-4
   PubMed Web of Science ®Google Scholar
• Catania C, Didier F, Leon ME, et al. Perception that oral anticancer treatments are less efficacious: development of a questionnaire to assess the possible prejudices of patients with cancer. Breast Cancer Res Treat 2005;92:265-72
   PubMed Web of Science ®Google Scholar
• Sedrakyan A, Van Der Meulen J, O’Byrne K, et al. Postoperative chemotherapy for non-small cell lung cancer: a systematic review and meta-analysis. J Thorac Cardiovasc Surg 2004;128:414-19
   PubMed Web of Science ®Google Scholar
• Bria E, Gralla RJ, Raftopoulos H, et al. Magnitude of benefit of adjuvant chemotherapy for non-small cell lung cancer: meta-analysis of randomized clinical trials. Lung Cancer 2009;63:50-7
   PubMed Web of Science ®Google Scholar
• Cortés ÁA, Urquizu LC, Cubero JH. Adjuvant chemotherapy in non-small cell lung cancer: state-of-the-art. Transl Lung Cancer Res 2015;4:191-7
   PubMed Web of Science ®Google Scholar
• Wakelee HA, Dahlberg SE, Keller SM. Randomized phase III trial of adjuvant chemotherapy with or without bevacizumab in resected non-small cell lung cancer (NSCLC): results of E1505. J Thorac Oncol Proc WCLC, 2015; Abstr:Plen04.03, 2015
   Google Scholar
• Vansteenkiste JF, Cho BC, Vanakesa T, et al. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3 positive non-small cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2016;17:822-35
   PubMed Web of Science ®Google Scholar
• Kelly K, Altorski NK, Eberhrdt WE, et al. Adjuvant erlotinib versus placebo in patients with stage IB-IIIA non small-cell lung cancer (RADIANT): a randomized double blind, phase III trial. J Clin Oncol 2015;33:4007-14
   PubMed Web of Science ®Google Scholar
• Zhong WZ, Wan Q,Mao WM, et al.: Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. Lancet Oncology 2018;19(1):139-148
   PubMed Web of Science ®Google Scholar